August 2022

Johnson & Johnson has announced that it will discontinue talc-based baby powder worldwide after two years of withdrawing sell of talc-based baby powder in the United States and Canada. The company will stop selling the product in the global market from 2023.

FDA found out cancer causing impurity in commonly used anti-diabetic medicines,  sitagliptin and notified in Drug safety report. FDA recently became aware of a nitrosamine impurity, Nitroso-STG-19 (known as NTTP), in certain samples of sitagliptin, a medicine used to treat type 2 diabetes mellitus.

Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to market Prochlorperazine Maleate tablets, USP 5 mg and 10 mg.

Prochlorperazine tablets are used to treat nervous, emotional, and mental conditions (eg. schizophrenia) and non-psychotic anxiety. It is also used to control severe nausea and vomiting. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.

Applications are invited from eligible candidates for recruitment to various posts in health institutions of (GUNTUR DISTRICT erstwhile district concerned) under the control of the DCHS/DM&HO/ Principals of Government Medical Colleges and Superintendents of Government General Hospitals (District Name) on Contract/Out sourcing basis.

Post : Pharmacist Gr-II

Applications are invited from eligible candidates for recruitment to various posts under District AIDS Prevention Control Committee, Kakinada.

Post : ART Pharmacist

No of posts : 01
Monthly remuneration : Rs. 21,000/-pm

IQVIA is the leading human data science company focused on helping healthcare clients find unparalleled insights and better solutions for patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness the power of healthcare data, domain expertise, transformative technology, and advanced analytics to drive healthcare forward.

Post : Clinical Research Associate

Established during the Swadeshi Movement of India, Biological E. Limited (BE) started during a time when the nation sought access to critical healthcare products. Founded and led by Dr. DVK Raju, Biological E. Limited commenced its operations in 1953 as a biological products company manufacturing liver extracts and anti-coagulants.  With an objective of transitioning from treating diseases to preventing them, Biological E.

Cipla, as an organisation has been built brick-by-brick on the foundation of care. Caring For Life has always been and continues to remain, our guiding purpose. Driven by the same purpose, we have extended our presence to 80+ countries providing over 1,500 products across various therapeutic categories in 50+ dosage forms. To make healthcare more affordable globally, we are deepening our presence in the key markets of India, South Africa, the U.S. among other economies of the emerging world.

Look back of growth drive for Indian pharmaceutical industry after 75 years of independence and future roadmap.

SAIL, a Maharatna Company, and a leading steel-making company in India with a turnover of 49350 crores (FY 2012-13) is in the process of modernizing and expanding its production units, raw material resources and other facilities to maintain its dominant position in the Indian steel market. Bokaro Steel Plant, one of the modernised integrated steel plants of SAIL employing a motivated workforce of around 18000 employees is producer of HR Coils/Sheets/Plates, CR Coils/ Sheets, GP Sheets/Coils.